Finan, C
Raina R, Chauvin A, Chakraborty R et al (2020) The role of endothelin and endothelin antagonists in chronic kidney disease
In addition, GLP-1 analogue treatment reduced all-cause mortality by 12%, hospital admission for heart failure by 9%, and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidney causes) by 17%, mainly due to a reduction in urinary albumin excretion [27]
Meanwhile, lawmakers in Louisiana are debating whether to allow Medicaid to cover GLP-1s for obesity treatment if enrollees have another chronic condition, or comorbidity, such as prediabetes, hypertension or cardiovascular disease
dollars, but the exchange rate they apply is usually less favorable than the market rate
Tirzepatide reduces input more efficiently